You may be wondering what mesenchymal stem cells are?
In actuality, the conversation surrounding “stem cell therapy” is known to be vast, complex, and occasionally contradictory.
At one end of the spectrum, you see strict regulations along with regulatory-approved cellular therapies tailored for critical medical conditions.
Conversely, at the other end lies a commercial marketplace that sells unverified interventions that far outpace current medical consensus.
In order to navigate this landscape responsibly, it is essential to put a focus on a single cell type positioned at the center of modern regenerative medicine.
This is the mesenchymal stem cell, or MSC.
Thus, taking all of this into consideration, the following article will offer a comprehensive, objective account of the following:
- What peer-reviewed clinical literature supports
- Where the biological mechanisms stand
- Where the evidence currently stands
First, What Are Mesenchymal Stem Cells
Before we can delve deep into the topic of mesenchymal stem cells, let us first understand what they are.
Mesenchymal stem cells, or MSCs, can be defined as multipotent adult stem cells which are capable of self-renewal and differentiation into specific cellular lineages.
Originally identified and isolated from adult bone marrow, subsequent scientific discovery confirmed their presence in various vascularized tissues.
This is most notably adipose (fat) tissue and the umbilical cord matrix. This umbilical cord matrix is also known as Wharton’s jelly.
Based on a foundational architecture of MSC research, this had shifted significantly in the late 20th century.
A seminal 1999 paper published in Science by Pittenger and colleagues demonstrated that cells isolated from adult human bone marrow could be extensively expanded in vitro.
This happens while maintaining their capacity to differentiate into multiple distinct tissue types.
In order to prevent diagnostic confusion within the expansion of the research community, the International Society for Cellular Therapy (ISCT) established minimum criteria in 2006.
This was to define human MSCs (Dominici et al., Cytotherapy, 2006). To be classified as an MSC, a cell must meet three core benchmarks:
| Criterion | Key Requirements & Markers | Description / Examples |
| Plastic Adherence | Adhere to plastic surfaces | Must attach to standard tissue culture flasks under normal culture conditions. |
| Surface Antigen Expression | • Positive (≥95%): CD105, CD73, CD90 • Negative (≤2%): CD45, CD34, CD14, HLA-DR | Must express specific stromal markers and lack hematopoietic or endothelial markers. |
| Trilineage Differentiation | • Osteoblasts • Adipocytes • Chondrocytes | Must be able to differentiate into bone, fat, and cartilage cells in vitro. |
Mechanistic Insights: How Do Mesenchymal Stem Cells Work?
Early paradigms in regenerative medicine have made presumptions that MSCs have been able to achieve therapeutic effects.
That is through direct engraftment and structural replacement. This means they have migrated to a site of injury and transformed into the missing tissue.
However, subsequent decades of cell biology altered this hypothesis.
MSC Secretion And Paracrine Signals
The accumulation of data suggests that the therapeutic impact of MSCs is primarily driven by their paracrine activity.
Instead of a permanent replacement of damaged tissues, MSCs tend to function as dynamic cellular factories. These tend to release a sophisticated mixture of bioactive molecules.
That includes:
- Cytokines
- Chemokines
- Growth factors
- Extracellular vesicles (exosomes)
These secreted signals interact with the resident immune cells of the patient in order to allow the mitigation of chronic inflammation.
Not just that, but it also allows the promotion of local tissue repair as well as altering the microenvironmental responses (Caplan and Correa, Cell Stem Cell, 2011).
Analysts view this as a pretty profound regulatory shift.
That is exactly why Arnold Caplan argued that the acronym MSC should be updated to mean “Medicinal Signaling Cells.” In this way, this would more accurately reflect their real-time physiological behavior (Stem Cells Translational Medicine, 2017).
Where The Evidence Is Strongest
The clearest signal is in graft-versus-host disease (GVHD), a serious complication of bone marrow transplants.
A phase II study reported responses in people whose disease no longer answered to steroids (Le Blanc et al., The Lancet, 2008).
Later single-arm phase 3 study in children continued that line (Kurtzberg et al., Biology of Blood and Marrow Transplantation, 2020).
In December 2024 the US FDA approved remestemcel-L (Ryoncil), a bone marrow-derived MSC product. This was for children with steroid-refractory acute GVHD (ISCT MSC committee statement, Cytotherapy, 2025).
An article in Blood described it as the first approved cell therapy for that condition (Etra, Ferrara and Levine, 2025).
That is a specific condition, a specific product and a specific population. It is not a general endorsement of MSCs.
Where The Clinical Evidence Remains Early
Beyond hematology, the utilization of MSCs for common degenerative conditions remains an active, yet preliminary, area of academic study.
Musculoskeletal Applications
The application of MSCs for knee osteoarthritis represents the most heavily documented area of orthopedic research.
In addition, early-phase, randomized controlled trials evaluating bone marrow-derived MSCs (Lamo-Espinosa et al., Journal of Translational Medicine, 2016) and umbilical cord-derived MSCs (Matas et al., Stem Cells Translational Medicine, 2019) have shown measurable improvements.
That is, in patient-reported pain scores and functional outcomes when compared against standard hyaluronic acid injections.
However, these early trials featured small sample sizes and brief follow-up periods.
Consequently, widespread clinical adoption requires large-scale, multi-center phase III trials to establish long-term efficacy, optimal dosing schedules, and precise patient selection criteria.
Healthy Aging And Longevity
Regarding the use of systemic MSC infusions for general healthy aging or longevity in healthy adults, no solid, placebo-controlled clinical trial shows that MSCs extend human healthspan or lifespan.
Presenting cellular therapy as an established, routine methodology for anti-aging is a claim that moves significantly ahead of peer-reviewed data.
Why The Field Is Hard To Read
A review in Cell Stem Cell by Galipeau and Sensébé (2018) lists the obstacles:
Cells vary by donor and tissue, manufacturing methods differ, and trial results have been inconsistent.
Meanwhile, Turner and Knoepfler mapped a sizable direct-to-consumer stem cell industry in the United States (Cell Stem Cell, 2016).
Moreover, research has documented the harms of unproven injections.
This includes a glioproliferative lesion of the spinal cord that they reported after overseas stem cell tourism (Berkowitz et al., New England Journal of Medicine, 2016).
What A Careful Provider Does With This
Takes the evidence at its true size.
At Healthi Life, a doctor-led longevity house in Ekkamai, Bangkok, MSC protocols are prescribed by a licensed physician after a medical consultation and written informed consent.
The cells come from ISO-certified, GMP-compliant partner labs, and the protocols are labeled investigational, with outcomes that vary.
Many people who ask are not eligible. Our page lays out the framework, the eligibility steps, and the published prices.
I started the house after my own stay in intensive care at 37. My co-founder, Dr. Petch, told me it would not happen again. The lesson I kept was simple: ask what the evidence says, then ask what it does not.
Disclaimer: Stem cell protocols at Healthi Life are given only after a medical consultation and on a physician’s prescription. The information provided in this article is for general informational purposes only. It does not, and is not intended to, constitute medical or health advice. Please consult a qualified healthcare professional for medical guidance or expert health assistance.
References
- Ding, D., Shyu, W., & Lin, S. (2011). Mesenchymal stem cells. Cell Transplantation, 20(1), 5–14. PubMed Central.
- Li, Z., Hu, X., & Zhong, J. F. (2019). Mesenchymal Stem Cells: Characteristics, Function, and Application. Stem Cells International, 2019, 8106818. PubMed Central.
- Lampiasi, N. (2024). Mesenchymal Stem Cells: What We Have Learned and How to Manage Them. Biology, 14(1), 1. PubMed Central.
